Which diabetes mellitus medications can cause hypoglycemia?

Diabetes Medications That Cause Hypoglycemia

The diabetes medications that cause hypoglycemia are insulin, sulfonylureas, and meglitinides—these are the only drug classes with clinically significant hypoglycemia risk when used alone. 1, 2, 3

High-Risk Medications

Insulin

• Carries dose-dependent hypoglycemia risk across all formulations (NPH, regular, rapid-acting analogs, long-acting analogs, and premixed combinations) 4
• Intensive insulin therapy (multiple daily injections, insulin pumps, automated insulin delivery) poses the highest hypoglycemia risk among all diabetes treatments 2, 3
• Basal insulin therapy carries lower but still substantial hypoglycemia risk compared to intensive regimens 2, 3
• Hypoglycemia risk increases when insulin is combined with sulfonylureas 4, 1

Sulfonylureas

• All sulfonylureas cause hypoglycemia by stimulating insulin secretion from pancreatic beta-cells in a glucose-independent manner 4, 5
• Glyburide (glibenclamide) presents the highest hypoglycemia risk among sulfonylureas and should be avoided, especially in older adults 6, 7, 8, 9
• Glipizide, glimepiride, and gliclazide have lower hypoglycemia rates compared to glyburide but still carry significant risk 4, 8
• When added to other glucose-lowering medications, sulfonylureas substantially increase hypoglycemia risk 10, 9
• Risk is amplified in patients with renal or hepatic dysfunction, older age (≥75 years), and those with cognitive impairment 4, 2, 3

Meglitinides (Glinides)

• Repaglinide and nateglinide stimulate insulin secretion similarly to sulfonylureas 11
• Lower hypoglycemia risk compared to sulfonylureas, particularly glyburide, but still clinically significant 11, 8, 9
• Can be used in patients with renal insufficiency where sulfonylureas are contraindicated 11

Medications with Minimal to No Hypoglycemia Risk

When Used as Monotherapy:

• Metformin: No hypoglycemia risk as monotherapy 4, 7
• DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin): Minimal hypoglycemia risk alone; however, when combined with sulfonylureas, hypoglycemia risk increases 50% 4, 11
• GLP-1 receptor agonists: No hypoglycemia as monotherapy, but increase risk when combined with insulin or sulfonylureas 6, 12
• SGLT2 inhibitors: No hypoglycemia risk as monotherapy 7, 12
• Thiazolidinediones (pioglitazone, rosiglitazone): No hypoglycemia as monotherapy, but may increase risk when combined with insulin or sulfonylureas 4, 11, 9
• α-Glucosidase inhibitors (acarbose, voglibose, miglitol): Very low hypoglycemia risk alone 11, 9

Critical Clinical Considerations

High-Risk Patient Populations:

• Recent (within 3-6 months) level 2 or 3 hypoglycemia 2, 3
• Impaired hypoglycemia awareness 2, 3
• End-stage kidney disease or eGFR <60 mL/min/1.73 m² 2, 3, 13
• Age ≥75 years 2, 3
• Cognitive impairment or dementia 2, 3
• Food insecurity or low-income status 2, 3

Important Pitfalls:

• Combination therapy dramatically increases hypoglycemia risk, particularly insulin plus sulfonylureas or sulfonylureas plus other secretagogues 12, 10
• Severe hypoglycemia requiring assistance (level 3) is rare with non-insulin, non-sulfonylurea, non-meglitinide medications 2, 3
• When α-glucosidase inhibitors are used, hypoglycemia must be treated with glucose or honey, not sucrose or starch, as these drugs block carbohydrate absorption 11